SY-005

DRUG2 trials

Sponsors

Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Conditions

Sepsis

Phase 1

Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects

CompletedNCT04217629

Suzhou Yabao Pharmaceutical R&D Co., Ltd.Sepsis

Start: 2019-04-26End: 2020-08-19Updated: 2021-06-03

Phase 2

SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis

Suzhou Yabao Pharmaceutical R&D Co., Ltd.Sepsis

Start: 2022-01-02End: 2023-07-01Target: 96Updated: 2022-03-14

Related Papers

Pharmacokinetics of recombinant human annexin A5 (SY-005) in patients with severe COVID-19

Frontiers in Pharmacology2024-01-105 citations